Zynerba Pharmaceuticals (NASDAQ:ZYNE) posted its quarterly earnings data on Wednesday. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.08, Fidelity Earnings reports.
Shares of ZYNE stock opened at $6.43 on Friday. Zynerba Pharmaceuticals has a 1 year low of $2.75 and a 1 year high of $16.47. The company’s fifty day simple moving average is $7.72 and its two-hundred day simple moving average is $11.02. The stock has a market capitalization of $165.40 million, a price-to-earnings ratio of -2.46 and a beta of 4.74.
Several research firms recently commented on ZYNE. ValuEngine upgraded Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $26.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Wednesday, September 18th. Jefferies Financial Group reiterated a “hold” rating and issued a $11.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Monday, September 16th. Finally, Needham & Company LLC started coverage on Zynerba Pharmaceuticals in a research note on Monday, October 21st. They issued a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $20.13.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Read More: What is a bull market?
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.